Skip to navigation Skip to content

News

Share

People with MS are not at greater risk from J&J COVID-19 vaccine

April 13, 2021

UPDATED: April 26, 2021

On April 23, 2021 The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) announced that administration of the Johnson & Johnson (J&J) COVID-19 vaccine should resume. The vaccine will now carry a warning about the risk for a blood clotting condition.

On April 13, 2021, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) issued a joint statement announcing a pause in the administration of the Johnson & Johnson (J&J) COVID-19 vaccine. This pause is occurring to give experts time to investigate reports of an extremely rare condition, a type of blood clot called cerebral venous sinus thrombosis (CVST), experienced by six women among the 6.8 million people who have received the J&J vaccine.

It is very early in this investigation but, currently, it does not appear that there is any additional risk for this extremely rare condition for those living with multiple sclerosis. The National MS Society’s COVID-19 vaccine advisory group continues to monitor safety data as they become available, and we will swiftly communicate any potential safety concerns specific to those living with MS. Check out the Society’s COVID-19 Resource Center for additional information about COVID-19 and MS.

For more information about the current pause, please visit the FDA website.  
 

En Español:

Las personas con EM no tienen mayor riesgo por la vacuna J&J contra el COVID-19

Ultima actualización: 26 de Abril del 2021 

El 23 de abril del 2021, los Centros para el Control y la Prevención de Enfermedades (CDC) y la Agencia Reguladora de Alimentos y Medicamentos (FDA) anunciaron que la administración de la vacuna contra el COVID-19 de Johnson & Johnson (J&J) debe reanudarse. La vacuna ahora llevará una advertencia sobre el riesgo de una condición de coagulación de la sangre.

El 13 de Abril del 2021, el Centro de Control y Prevención de Enfermedades (CDC) y la Agencia Reguladora de Alimentos y Medicamentos (FDA) emitieron una declaración conjunta anunciando una pausa en la administración de la vacuna contra el COVID-19 de Johnson & Johnson (J&J). Esta pausa está ocurriendo para dar tiempo a los expertos para investigar reportes de una condición extremadamente rara, un tipo de coágulo sanguíneo llamado trombosis del seno venoso cerebral (CVST), experimentado por seis mujeres entre los 6,8 millones de personas que han recibido la vacuna J&J.

Es muy temprano en esta investigación, pero, actualmente, no parece que haya ningún riesgo adicional para esta condición extremadamente rara para aquellos que viven con esclerosis múltiple. El grupo asesor de las vacunas contra el COVID-19 de la Sociedad Nacional de EM continúa monitoreando los datos de seguridad a medida que estén disponibles, y comunicaremos rápidamente cualquier posible preocupación de seguridad específica para aquellos que viven con EM. Visite el Centro de Recursos de COVID-19 de la Sociedad para obtener información adicional sobre COVID-19 y EM.

Para obtener más información sobre la pausa actual, visite el sitio web de la FDA.

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. There is currently no cure for MS. Symptoms vary from person to person and range from numbness and tingling, to mobility challenges, blindness and paralysis. An estimated 1 million people live with MS in the United States. Most people are diagnosed between the ages of 20 and 50, and it affects women three times more than men.

About the National Multiple Sclerosis Society

The National MS Society, founded in 1946, funds cutting-edge research, drives change through advocacy, and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, Twitter, Instagram, YouTube or 1-800-344-4867.

Share


© 2021 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.